Lexaria Bioscience

Investor Insight

Lexaria Bioscience is a US and Canada-based company developing a patented drug delivery technology that improves oral bioavailability and tolerability of active pharmaceutical ingredients (APIs), including GLP-1 drugs.

Overview

The global anti‑obesity medication (AOM) market is expected to grow at a 13 to 15 percent annual rate through 2034. GLP‑1 drugs are driving the surge in weight loss treatments, therefore increasing innovation in oral GLP‑1 delivery.

US$22.37M company Lexaria Bioscience (NASDAQ:LEXX) is focused on making these therapies more tolerable and convenient for patients without reducing efficacy.

The biotech’s proprietary platform is called DehydraTECH™, aimed at improving the performance and intake experience of orally administered drugs. By enhancing performance and reducing side effects, Lexaria aims to set a new standard for oral therapeutics while building licensing opportunities with major pharmaceutical partners.

DehydraTECH has been in advanced research and development since 2015, initially centered on studies assessing pharmacokinetics. At least 65 patents of the technology have been granted, while others are pending applications to diabetes, hypertension-related conditions, epilepsy, antiviral drugs, central nervous system conditions, phosphodiesterase type 5 inhibitors and others.

The company is focusing on looking at its technology to blockbuster drug classes, specifically GLP‑1 receptor agonists used in diabetes and obesity treatments. Lexaria is working with pharmaceutical partners to bring this innovation into commercial products. Results from both human and animal studies have been encouraging, showing stronger drug performance and better tolerability. Backed by a growing patent portfolio and ongoing research, Lexaria is moving closer to licensing deals and broader commercialization opportunities.

Company Highlights

• Proprietary DehydraTECH™ platform improves oral bioavailability and tolerability of active pharmaceutical ingredients (APIs), including GLP-1 drugs
• 65 patents granted globally across multiple sectors, with more awaiting
• Positive human and preclinical study results demonstrating improved absorption and reduced side effects in GLP-1 drug formulations
• Positioned to capitalize on rapid growth in oral GLP-1 treatments following recent FDA approvals, including Novo Nordisk’s Wegovy® pill and Eli Lilly’s Foundayo™

Key Project

DehydraTECH™ is Lexaria’s core technology, a patented formulation and processing platform that enhances oral drug delivery. It enables faster and more efficient absorption of APIs, with evidence showing improved bioavailability and reduced side effects. The platform is designed for use across multiple delivery formats, including capsules, tablets (pills) and oral suspensions.

The company is actively evaluating DehydraTECH™ in combination with leading GLP-1 drugs. According to Lexaria, DehydraTECH is the only technology publicly disclosed for its ability to reduce side effects in 3 of the top GLP-1 drugs currently sold in the world today: semaglutide, tirzepatide and liraglutide.

Recent FDA approvals of Novo Nordisk’s Wegovy® pill and Eli Lilly’s oral GLP-1 drug Foundayo™ highlight growing demand for non-injectable therapies. Lexaria believes its technology can improve patient experience particularly by reducing side effects, positioning it as a valuable partner for pharmaceutical companies entering or expanding within the oral GLP-1 market.

The company is initiating a new human clinical study (GLP-1-H26-7) as part of its 2026 R&D program to further evaluate DehydraTECH™-enhanced oral GLP-1 formulations. The study is designed as a multi-week, parallel-group trial assessing safety, tolerability and pharmacokinetics across different dosing formats. It also builds on prior human data that demonstrated improved absorption and reduced side effects versus conventional GLP-1 therapies.

The program is intended to generate additional clinical validation, support intellectual property expansion and strengthen Lexaria’s positioning for potential pharmaceutical partnerships in the rapidly growing oral GLP-1 market.

Management Team

Richard Christopher – Chief Executive Officer

Richard Christopher brings extensive financial and operational experience across biotechnology and medical technology companies. He has held various C-suite leadership roles at InVivo Therapeutics, iCAD and Caliber Imaging & Diagnostics, and previously served as CFO of DUSA Pharmaceuticals through its acquisition by Sun Pharmaceutical Industries.

John Docherty – President and Chief Scientific Officer

John Docherty has over 20 years of experience in pharmaceuticals and drug development. Formerly President and COO of Helix BioPharma, he has led development programs, strategic partnerships and capital markets initiatives. He is a named inventor on multiple patents.

Michael Shankman – Chief Financial Officer

Michael Shankman has broad financial leadership experience across biotechnology, medical devices and SaaS sectors. He has previously supported Lexaria’s financial reporting and audit functions and has served as an outsourced CFO to multiple organizations.

Chris Bunka – Chairman of the Board

Chris Bunka is a serial entrepreneur and former CEO of Lexaria who led its transition into biosciences. He has extensive experience in capital markets, corporate governance and corporate finance, and is a named inventor on company patents.